Consolidated Management Report

The report records consolidated 2023 turnover of €337.4m and R&D investment of €57.6m, while describing continued development of the BIA28 project after its first patient entered the Phase II trial. It also reports a 52% reduction in Scope 1 and Scope 2 GHG emissions compared with 2020, and states that its production and self-consumption unit generated 945 MWh, equal to 19% of total electricity consumption.